The effects of simvastatin treatment on plasma lipid-related biomarkers in men with dyslipidaemia

References

• Bergheanu SC, Reijmers T, Zwinderman AH, Bobeldijk I, Ramaker R, Liem AH, van der Greef J, Hankemeier T, Jukema JW. (2008). Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Curr Med Res Opin 24:2477–2487.
   PubMed Web of Science ®Google Scholar
• Berk-Planken II, Hoogerbrugge N, Stolk RP, Bootsma AH, Jansen H; DALI Study Group. (2003). Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant. Diabetes Care 26:427–432.
   PubMed Web of Science ®Google Scholar
• Bitzur R, Cohen H, Kamari Y, Shaish A, Harats D. (2009). Triglycerides and HDL cholesterol: stars or second leads in diabetes? Diabetes Care 32 (Suppl 2):S373–S377.
   PubMed Web of Science ®Google Scholar
• Branchi A, Fiorenza AM, Rovellini A, Torri A, Muzio F, Macor S, Sommariva D. (1999). Lowering effects of four different statins on serum triglyceride level. Eur J Clin Pharmacol 55:499–502.
   PubMed Web of Science ®Google Scholar
• Branchi A, Rovellini A, Fiorenza AM, Sommariva D. (1995). Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients. Int J Clin Pharmacol Ther 33:345–350.
   PubMed Web of Science ®Google Scholar
• Bredie SJ, Westerveld HT, Knipscheer HC, de Bruin TW, Kastelein JJ, Stalenhoef AF. (1996). Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia. Neth J Med 49:59–67.
   PubMed Web of Science ®Google Scholar
• Browning JD, Horton JD. (2010). Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. J Lipid Res 51:3359–3363.
   PubMed Web of Science ®Google Scholar
• Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ. (2008). Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 49:394–398.
   PubMed Web of Science ®Google Scholar
• Castro Cabezas M, de Bruin TW, Van Linde-Sibenius Trip M, Kock LA, Jansen H, Erkelens DW. (1993). Lipoprotein(a) plasma concentrations associated with lipolytic activities in eight kindreds with familial combined hyperlipidemia and normolipidemic subjects. Metab Clin Exp 42:756–761.
   PubMed Web of Science ®Google Scholar
• Castro Cabezas M, Verseyden C, Meijssen S, Jansen H, Erkelens DW. (2004). Effects of atorvastatin on the clearance of triglyceride-rich lipoproteins in familial combined hyperlipidemia. J Clin Endocrinol Metab 89:5972–5980.
   PubMed Web of Science ®Google Scholar
• Cheung BM, Lauder IJ, Lau CP, Kumana CR. (2004). Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 57:640–651.
   PubMed Web of Science ®Google Scholar
• Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, Prat A. (2004). Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 24:1454–1459.
   PubMed Web of Science ®Google Scholar
• Endo A. (1992). The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 33:1569–1582.
   PubMed Web of Science ®Google Scholar
• Folch J, Lees M, Sloane Stanley GH. (1957). A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497–509.
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Brown MS. (2009). The LDL receptor. Arterioscler Thromb Vasc Biol 29:431–438.
   PubMed Web of Science ®Google Scholar
• Haffner S, Orchard T, Stein E, Schmidt D, LaBelle P. (1995). Effect of simvastatin on Lp(a) concentrations. Clin Cardiol 18:261–267.
   PubMed Web of Science ®Google Scholar
• Harris JI, Hibbeln JR, Mackey RH, Muldoon MF. (2004). Statin treatment alters serum n-3 and n-6 fatty acids in hypercholesterolemic patients. Prostaglandins Leukot Essent Fatty Acids 71:263–269.
   PubMed Web of Science ®Google Scholar
• Hodson L, Skeaff CM, Fielding BA. (2008). Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. Prog Lipid Res 47:348–380.
   PubMed Web of Science ®Google Scholar
• Horton JD, Cohen JC, Hobbs HH. (2007). Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 32:71–77.
   PubMed Web of Science ®Google Scholar
• Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, Brown MS, Goldstein JL. (2003). Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci USA 100:12027–12032.
   PubMed Web of Science ®Google Scholar
• Hrboticky N, Tang L, Zimmer B, Lux I, Weber PC. (1994). Lovastatin increases arachidonic acid levels and stimulates thromboxane synthesis in human liver and monocytic cell lines. J Clin Invest 93:195–203.
   PubMed Web of Science ®Google Scholar
• Isley WL, Miles JM, Patterson BW, Harris WS. (2006). The effect of high-dose simvastatin on triglyceride-rich lipoprotein metabolism in patients with type 2 diabetes mellitus. J Lipid Res 47:193–200.
   PubMed Web of Science ®Google Scholar
• Jula A, Marniemi J, Rönnemaa T, Virtanen A, Huupponen R. (2005). Effects of diet and simvastatin on fatty acid composition in hypercholesterolemic men: a randomized controlled trial. Arterioscler Thromb Vasc Biol 25:1952–1959.
   PubMed Web of Science ®Google Scholar
• Kaddurah-Daouk R, Baillie RA, Zhu H, Zeng ZB, Wiest MM, Nguyen UT, Watkins SM, Krauss RM. (2010). Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study. Metabolomics 6:191–201.
   PubMed Web of Science ®Google Scholar
• Kobayashi J, Maruyama T, Masuda M, Shinomiya M. (2001). Effect of atorvastatin treatment on lipoprotein lipase mass in the pre-heparin plasma in Japanese hyperlipidemic subjects. Clin Chim Acta 314:261–264.
   PubMed Web of Science ®Google Scholar
• Labreuche J, Touboul PJ, Amarenco P. (2009). Plasma triglyceride levels and risk of stroke and carotid atherosclerosis: a systematic review of the epidemiological studies. Atherosclerosis 203:331–345.
   PubMed Web of Science ®Google Scholar
• Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. (2009). Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 94:2537–2543.
   PubMed Web of Science ®Google Scholar
• Lambert G, Charlton F, Rye KA, Piper DE. (2009). Molecular basis of PCSK9 function. Atherosclerosis 203:1–7.
   PubMed Web of Science ®Google Scholar
• Macy EM, Hayes TE, Tracy RP. (1997). Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 43:52–58.
   PubMed Web of Science ®Google Scholar
• Maron DJ, Fazio S, Linton MF. (2000). Current perspectives on statins. Circulation 101:207–213.
   PubMed Web of Science ®Google Scholar
• Mead JR, Irvine SA, Ramji DP. (2002). Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med 80:753–769.
   PubMed Web of Science ®Google Scholar
• Mehrotra DV, Heyse JF. (2004). Use of the false discovery rate for evaluating clinical safety data. Stat Methods Med Res 13:227–238.
   PubMed Web of Science ®Google Scholar
• Nakamura MT, Nara TY. (2004). Structure, function, and dietary regulation of delta6, delta5, and delta9 desaturases. Annu Rev Nutr 24:345–376.
   PubMed Web of Science ®Google Scholar
• Nordøy A, Hansen JB, Brox J, Svensson B. (2001). Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. Nutr Metab Cardiovasc Dis 11:7–16.
   PubMed Web of Science ®Google Scholar
• Perret B, Mabile L, Martinez L, Tercé F, Barbaras R, Collet X. (2002). Hepatic lipase: structure/function relationship, synthesis, and regulation. J Lipid Res 43:1163–1169.
   PubMed Web of Science ®Google Scholar
• Piorunska-Stolzmann M, Piorunska-Mikolajczak A, Mikolajczyk Z. (2003). Effect of simvastatin on trioleylglycerol hydrolysis and transacylation with cholesterol in serum of outpatients with coronary heart disease. Drugs Exp Clin Res 29:37–43.
   PubMedGoogle Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). (1994). Lancet 344:1383–1389.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group. (2009). Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373:1175–1182.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Khurmi NS, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group. (2007). Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol 100:1659–1664.
   PubMed Web of Science ®Google Scholar
• Risé P, Colombo C, Galli C. (1997). Effects of simvastatin on the metabolism of polyunsaturated fatty acids and on glycerolipid, cholesterol, and de novo lipid synthesis in THP-1 cells. J Lipid Res 38:1299–1307.
   PubMed Web of Science ®Google Scholar
• Risé P, Ghezzi S, Galli C. (2003). Relative potencies of statins in reducing cholesterol synthesis and enhancing linoleic acid metabolism. Eur J Pharmacol 467:73–75.
   PubMed Web of Science ®Google Scholar
• Risé P, Pazzucconi F, Sirtori CR, Galli C. (2001). Statins enhance arachidonic acid synthesis in hypercholesterolemic patients. Nutr Metab Cardiovasc Dis 11:88–94.
   PubMed Web of Science ®Google Scholar
• Schneider JG, von Eynatten M, Parhofer KG, Volkmer JE, Schiekofer S, Hamann A, Nawroth PP, Dugi KA. (2004). Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo. Atherosclerosis 175:325–331.
   PubMed Web of Science ®Google Scholar
• Schönbeck U, Libby P. (2004). Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109:II18–II26.
   PubMed Web of Science ®Google Scholar
• Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatka A, Wang PR, Zhang D, Peterson L, Detmers PA, Chao YS, Wright SD. (2001). Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 21:115–121.
   PubMed Web of Science ®Google Scholar
• Superko HR, King S 3rd. (2008). Lipid management to reduce cardiovascular risk: a new strategy is required. Circulation 117:560–568; discussion 568.
   PubMed Web of Science ®Google Scholar
• The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. (2001). Diabetes Care 24:1335–1341.
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. (2002). Circulation 106:3143–3421.
   PubMed Web of Science ®Google Scholar
• Toutouzas K, Drakopoulou M, Skoumas I, Stefanadis C. (2010). Advancing therapy for hypercholesterolemia. Expert Opin Pharmacother 11:1659–1672.
   PubMed Web of Science ®Google Scholar
• Wang Y, Botolin D, Xu J, Christian B, Mitchell E, Jayaprakasam B, Nair MG, Nair M, Peters JM, Peters JM, Busik JV, Busik J, Olson LK, Jump DB. (2006). Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity. J Lipid Res 47:2028–2041.
   PubMed Web of Science ®Google Scholar
• Weiss EP, Fields DA, Mittendorfer B, Haverkort MA, Klein S. (2008). Reproducibility of postprandial lipemia tests and validity of an abbreviated 4-hour test. Metab Clin Exp 57:1479–1485.
   PubMed Web of Science ®Google Scholar
• Wenk MR. (2005). The emerging field of lipidomics. Nat Rev Drug Discov 4:594–610.
   PubMed Web of Science ®Google Scholar
• Williams ML, Menon GK, Hanley KP. (1992). HMG-CoA reductase inhibitors perturb fatty acid metabolism and induce peroxisomes in keratinocytes. J Lipid Res 33:193–208.
   PubMed Web of Science ®Google Scholar
• Zambon A, Deeb SS, Brown BG, Hokanson JE, Brunzell JD. (2001). Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation 103:792–798.
   PubMed Web of Science ®Google Scholar